DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that Ellipsis Biotherapeutics, Inc. will complete a record quarter of revenue generation from high volume SNP genotyping. A significant portion of the revenue came from four contracts, including a major American university, two United Kingdom academic research groups, and one Toronto based academic hospital program. Ellipsis, acquired by the Company in November 2005, conducts SNP genotyping using state-of-the-art technologies. These include single-base primer extension platforms from Beckman Coulter, Inc. and the GoldenGate™ platform from Illumina, Inc. With a choice of platforms and scales for performing work, Ellipsis supports companies through the entire scope of their genotyping efforts. Projects include both high throughput screening of multiple samples as well as finer mapping to clarify associations of genetic predisposition in a variety of human diseases.

“Our goal is to deliver the highest quality SNP genotyping services to the marketplace, including project development, ongoing scientific advice and data analysis and interpretation,” commented Dr. Laurence Rubin, founder of Ellipsis. “Ellipsis has completed these projects on schedule and within budget. Our services have been instrumental in helping scientists publish their work in respected scientific journals. In addition to completing large volume contract services for a variety of projects, we are participating in novel research programs, which has always been part of the company’s focus,” he added.

“We are extremely pleased that Ellipsis Biotherapeutics has met its first major milestone and has done it with better than budgeted goals and objectives. We expect that Ellipsis will continue to contribute to our revenue growth and assist our core pursuit of pharmaceuticals and diagnostics,” said Richard Gabriel, Chief Executive Officer and President of DNAPrint Genomics, Inc.

For further information on genotyping and other DNA services, please contact Ellipsis Biotherapeutics at: 416-586-0947.

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company for additional forensics work. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results. The Company also performs contract genotyping and other DNA services through its Ellipsis Biotherapeutics group in Toronto, Canada.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation, to release publicly any updates or revisions to any forwardlooking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced the expansion of the Company’s high-throughput genotyping capacity from 1.3 million to more than 3.9 million genotypes per day.

“Multiplexing and advanced automation protocols provide the flexibility to process large or small genotyping studies without compromising cost per genotype,” stated DNAPrint Genomics President and Chief Executive Officer Richard Gabriel. “Increasing high-volume throughput advances our ability to determine genotypes at economical costs to our customers and business partners. Coupled with our population ancestry technology, we can achieve better research results at a business-smart price.”

The increase in processing capacity particularly targets the pharmaceuticals and healthcare market. It enables the Company to process clinical trials samples to ensure that patient population groups are accurately categorized, and perform large scale genotyping work for the various industries interested.

DNAPrint Genomics Founder and Chief Scientific Officer Tony N. Frudakis, Ph.D., noted that the Company has key advantages over other laboratories offering genotyping services. “We are unique in our expertise in population structure analysis using our Ancestry Informative Markers (AIM),” said Dr. Frudakis. “We can demonstrate to our customers that failure to understand the ancestral or biological structure of their study population can significantly confound and even compromise genetic studies. We offer a unique approach to maximizing the probability of success in pharmacogenetic, predisposition, risk profiling and susceptibility studies t h at many companies are pursuing alongside drug and diagnostics development.”

DNA Print has genotyping facilities at its Sarasota headquarters and at laboratories in Richmond, Calif., and Toronto, Canada, which utilize sophisticated equipment manufactured by Beckman Coulter and Illumina, Inc. The U.S. laboratories are genotyping with the ultra sensitive and robust GenomeLab SNPstream from Beckman Coulter while the Toronto lab is equipped with the Illumina bead machine and is also offering HAP MAP SNP genotyping services.

“Results from the GenomeLab SNPstream from Beckman Coulter are 99+% reproducible, providing the kind of validation that we believe the U.S. Food and Drug Administration (FDA) is seeking for its clinical trials data,” Dr. Frudakis noted.

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). Recently announced and as a part of the Company’s Trace Genetics acquisition, DNAWitness-Y and DNAWitness-Mito are two new tests that can be used as an identification tool when other DNA testing either fails to yield results or the sample might be too deteriorated.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation, to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced the completion of its previously announced acquisition of Ellipsis Biotherapeutics Corporation, which will operate as a drug and diagnostic subsidiary.

Ellipsis Biotherapeutics, formerly privately held, is retaining its name and will function as a Canadian company from its corporate headquarters in Toronto, Ontario. Ellipsis will retain its existing personnel and continue to be managed by Dr. Laurence Rubin, who is also the Director of the Division of Rheumatology at St. Michael's Hospital in Toronto. His research has focused on the genetic determinants of osteoporosis, rheumatoid arthritis and other inflammatory diseases. He has been with Ellipsis since 2000.

“The Ellipsis Biotherapeutics acquisition strengthens our position in the diagnostic and clinical patient testing market,” stated Richard Gabriel, Chief Executive Officer and President of DNAPrint Genomics. “It also provides potential business opportunities with several large pharmaceutical and animal health care companies currently utilizing Ellipsis’s high throughput screening technologies.”

Ellipsis is located in downtown Toronto in close proximity to the University of Toronto campus, the recently opened MaRS Centre and major academic teaching hospitals. Using the Beckman Coulter GenomeLab SNPstream and the Illumina Beadstation, Ellipsis performs contract SNP genotyping for academic centers, hospitals, human health care corporations and biotech companies in diverse areas covering human, plant and animal analyses. In addition, Ellipsis has acquired a diverse portfolio of genetic data and intellectual property from unique patient populations, specifically with Inflammatory Bowel Disease (Crohn’s disease) including last year’s publications of the discovery of a gene for Crohn’s disease. Diagnostic applications are currently under development in this and related areas of autoimmune inflammatory disorders.

“We are very excited to be part of the DNAPrint group of companies,” Dr. Laurence Rubin stated. “Our core competencies provide a unique fit for future growth and development of our contract services as well as opportunities to accelerate novel research programs and collaborations.”

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM).

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Ellipsis Biotherapeutics Corporation announced today that it now offers SNP genotyping using both the Illumina GoldenGate™ and Beckman Coulter SNPstream™ technologies.

“The addition of the Illumina system to our existing SNPstream platform allows us the unique opportunity to accomodate all SNP genotyping projects, ranging in size from quite small to very large”, commented Laurence Rubin, CEO of Ellipsis. “We are very excited to offer this complete suite of SNP genotyping solutions to our clients”.

Ellipsis Biotherapeutics Corporation was founded in 1997 to commercialize the disease gene discovery efforts of its founders, primarily in the area of inflammatory disease. Since then, it has leveraged its expertise in SNP genotyping to provide high quality service to a variety of clients in academic, government and industrial research settings. For more information, see the company’s website at www.ellipsisbio.com, or contact genotyping@ellipsisbio.com.

Findings Published in Nature Genetics.

Ellipsis Biotherapeutics Corporation, a drug and diagnostics discovery company, together with academic collaborators, has isolated novel genes that predispose people to development of Crohn's disease. Their findings appeared online April 11 in the journal Nature Genetics (www.nature.com/ng/) and are published in the current issue of the journal.

"Isolating this gene is a critical step towards improved diagnosis of this disease and developing better therapies for Crohn's sufferers, who have an urgent need for better treatment" says Katherine Siminovitch, President and Chief Operating Officer of Ellipsis. Crohn's disease is an inflammatory bowel disease of increasing prevalence in industrialized nations. Existing treatments are considered unsatisfactory, often requiring recurring hospitalization and surgeries.

The Crohn's discovery was made using Ellipsis' genetic analysis technologies to identify genes using DNA samples from family groups. The identified genes produce proteins that sit on the surface of cells lining the gastro-intestinal tract and regulate how substances enter and exit these cells. In a majority of Crohn's disease patients, these proteins function improperly and allow toxins easier access to the cell.

The ability to test for this altered protein will help physicians distinguish between Crohn's disease and ulcerative colitis, the other major form of inflammatory bowel disease known. The alteration discovered by Ellipsis and its collaborators is not present in ulcerative colitis, so this gene alteration provides a diagnostic test to help distinguish between the two diseases. Ellipsis anticipates that this information can also be used to diagnose Crohn's disease at an earlier stage and to develop new approaches to treatment. The discovery of these novel genes will also enable the development of small molecules that can regulate these disease pathways.

"We are very excited about this discovery," says Siminovitch. "It provides further demonstration of the success of Ellipsis technologies and sheds light on the biological processes that lead to many chronic inflammatory conditions, such as Crohn's disease and rheumatoid arthritis, which have similar causes even though the target organs differ."

Ellipsis Biotherapeutics Corporation is a privately held drug and diagnostic discovery company developing novel medicines for human diseases where existing therapies are unable to address patient needs. The company's lead programs are in Alzheimer's Disease and Inflammatory Bowel Disease, where new treatment regimens are needed not only to treat symptoms, but to prevent and cure the underlying disorder. Through both independent programs and strategic alliances, Ellipsis intends to commercialize its discoveries and make better medicines for patients.

Staff from Ellipsis Biotherapeutics Corporation's SNP genotyping service will present a web-based seminar entitled "Automated scalable SNP genotyping solutions using the GenomeLab SNPstream genotyping system". The seminar, hosted by Beckman Coulter, Inc., will be on Thursday, April 15, 2004, at 12:00 noon EST. Please visit www.beckmancoulter.com/SNPseminar for details and registration.